Company: IR
Filing Date: 2025-10-31
Form Type: 10-Q
Source: 0001628280-25-047838
Chunk: 130

Company: Ingersoll Rand Inc.
Filing Date: 2025-10-31
Form: 10-Q
Item: Part I, Item 8
Chunk 130
---
, 2025 and December 31, 2024. Accumulated impairment losses within the Precision and Science Technologies segment was $229.7 million and $0.0 million as of September 30, 2025 and December 31, 2024, respectively.Other Intangible Assets, NetOther intangible assets as of September 30, 2025 and December 31, 2024 consisted of the following.September 30, 2025December 31, 2024Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying AmountAmortized intangible assetsCustomer lists and relationships$4,258.2 $(2,111.3)$2,146.9 $4,010.1 $(1,830.1)$2,180.0 Technology568.3 (302.6)265.7 549.1 (243.3)305.8 Tradenames80.0 (38.6)41.4 63.6 (32.4)31.2 Backlog— — — 4.3 (4.2)0.1 Other160.1 (123.0)37.1 128.5 (112.1)16.4 Unamortized intangible assetsTradenames1,828.5 — 1,828.5 1,839.3 — 1,839.3 Total other intangible assets$6,895.1 $(2,575.5)$4,319.6 $6,594.9 $(2,222.1)$4,372.8 Intangible Asset Impairment ConsiderationsDuring the second quarter of 2025, certain organizational changes occurred that impacted the composition of all reporting units within our Precision and Science Technologies segment. As a result of these changes, the Company performed an interim goodwill impairment test for all affected reporting units, utilizing a combination of an income and market approach weighted 75% and 25%, respectively, to determine the fair value.In the second quarter of 2025, the Company recognized non-cash impairments of $170.3 million and $59.4 million to reduce the carrying value of goodwill of our Biopharma and Aerospace & Defense reporting units, respectively. Both the Biopharma and Aerospace &